Press Releases

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

EAGAN, MN — December 4, 2019 — Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in chemo-refractory metastatic triple negative breast cancer patients have been selected for a poster discussion Spotlight Session on December 11 at the 2019 San Antonio Breast Cancer Symposium. Spotlight...

Read More


Biothera Pharmaceuticals Presents Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and Overall Survival EAGAN, MN — November 8, 2019 — Biothera Pharmaceuticals, Inc. announced today immune pharmacodynamic data from its Phase 2 clinical study evaluating the therapeutic combination of Imprime PGG and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in chemo-refractory metastatic triple...

Read More


Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in triple negative breast cancer and melanoma this week at the Society for Immunotherapy of Cancer annual meeting in the Gaylord...

Read More


Tamas Mir Named Senior Vice President, Finance; CFO Andrew D. C. LaFrence Resigns to Pursue New Opportunity

EAGAN, MN — August 6, 2019 — Biothera Pharmaceuticals, Inc. today announced the appointment of Tamas Mir as Senior Vice President, Finance with responsibility for all finance functions, Human Resources and Information Technology.  Mr. Mir joined Biothera in 2012 as Corporate Controller and was promoted the following year to Vice President, Finance.  Mr. Mir replaces Andrew D. C. LaFrence, who has left Biothera for a...

Read More


Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate (Three previous TNBC clinical studies with checkpoint inhibitor (CPI) monotherapies generated response rates of 5% to 6%) 25% Disease Control Rate >24 weeks 13.7 months median Overall Survival, with 64.2% patient survival at 12 months...

Read More


Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

Study Evaluating Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® EAGAN, MN — May 16, 2019 — Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary clinical data from its phase 2 study in chemo-refractory metastatic triple negative breast cancer at the American Society of Clinical Oncology (ASCO) 2019 annual meeting, May...

Read More


Biothera Pharmaceuticals to Present at the Needham & Company Healthcare Conference

EAGAN, MN — April 2, 2019 — Biothera Pharmaceuticals, Inc. today announced that Jeremy Graff, Ph.D., President and Chief Scientific Officer, and Andrew D. C. LaFrence, Senior Vice President and Chief Financial Officer, will present at the Needham & Company 18th Annual Healthcare Conference on April 9 at 3:10 PM Eastern Time in New York City. About Biothera Pharmaceuticals, Inc. Biothera Pharmaceuticals is a privately...

Read More


Biothera Pharmaceuticals to Participate in Webinar on Utilizing Innate Immune Mechanisms to Trigger Anti-Cancer Responses

EAGAN, MN — March 25, 2019 — Biothera Pharmaceuticals, Inc. President and Chief Scientific Officer Jeremy Graff, Ph.D., will participate in a webinar tomorrow on the development of therapies targeting innate immune mechanisms to overcome cancer defenses and initiate anti-tumor responses.  The Scientist magazine will host the webinar, “Keeping Cancer in Check: Innate Immunity and Checkpoint Inhibitors,” from 2:30-4:00pm Eastern Time.  Registration is free. In...

Read More


Biothera Pharmaceuticals Announces Management Changes

EAGAN, MN — December 13, 2018 — Biothera Pharmaceuticals, Inc. announced today that Chief Executive Officer Barry Labinger has resigned to pursue another opportunity, effectively immediately.  Biothera Holding Corp. Chairman Richard Mueller has been appointed acting CEO.  Jeremy Graff, Ph.D., has been named President in addition to his position as Chief Scientific Officer.  Dr. Graff will have responsibility for Research, Clinical Operations and Manufacturing.  Since...

Read More


Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer EAGAN, MN — September 5, 2018 — Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI®) can decrease tumor volume in patients with primary untreated locally...

Read More



Page 1 of 3123